NICE describes itself as providing ‘independent, authoritative and evidence-based guidance on the most effective ways to prevent, diagnose and treat disease and ill health’.
The medical profession should therefore expect NICE to base its findings on full data disclosure and independently evaluated cost-benefit of statins. Simply asserting that it is independent seems unconvincing.
I believe such guidance would not have the confidence of the majority of GPs charged with its implementation. In May 2014 the LMCs conference passed a unanimous motion calling for NICE to recommend such changes only on the basis of a full disclosure of trial data.
I developed side-effects